This presentation will overview the four areas of hypersensitivity: immediate Type I IgE-mediated, Type II antibody-dependent cytotoxicity, Type III immune-complex-mediated, and delayed-Type hypersensitivity. Type I human allergic disease will then be examined, covering its pathophysiology, current diagnostic strategies, four modes of disease management, and special caveats relating to food, drug, venom, and respiratory allergic disease. Finally, the new discipline of molecular allergology will be highlighted with an emphasis on ten cross-reactive allergen families and how allergenic molecules have improved the accuracy of allergy diagnosis.

Immune checkpoint inhibitors, bispecific antibodies, and antibody-drug conjugates have reshaped oncology, but each carries distinct and sometimes overlapping immunological safety risks. This presentation reviews major toxicity mechanisms, including loss of immune tolerance, cytokine release, effector-cell overactivation, and inflammatory tissue injury. Drawing on cross-modality case examples, it highlights how target biology, molecular format, payload properties, and dose schedule influence clinical safety outcomes. The session also discusses practical approaches to improving therapeutic index, including translational nonclinical assessment, biomarker-guided monitoring, patient selection, and proactive clinical mitigation. Attendees will gain a concise framework for anticipating and managing immunological risk across these evolving platforms.

Understanding the immunogenicity of biopharmaceuticals is essential to ongoing product development, clinical use and regulatory approval. Numerous risk factors may provoke immune responses, potentially reducing efficacy and, in some cases, leading to safety concerns such as hypersensitivity reactions, immune complex syndromes and autoimmune disorders. This overview examines factors influencing immune responses to biotherapeutics, clinical impact of unwanted immunogenicity and mitigation strategies to improve patient outcomes.

While it has been long appreciated that liver-derived systemic complement guards the vascular space, it has been more recently recognized that cell intrinsic and/or intracellularly derived complement components play pivotal roles in tissue immunity through the regulation of normal cell physiology, metabolism, survival, and effector functions in a plethora of cell types in the human body. Our lab studies the role of cell-autonomous complement in immune and non-immune cells and its role in homeostasis and disease (infection, cancer and autoimmunity) to further our understanding of how this system can be targeted therapeutically.

CD28 and 4-1BB are two indispensable costimulatory receptors on T cells playing key role in tumor immunity and my talk can help understand the risk and benefit of engaging CD28 and 4-1BB by agonistic antibodies. I will provide a comprehensive background on costimulatory receptors CD28 and 4-1BB and then dive deep into the mechanisms of actions by showing first hand data from innovative in vitro assay platforms.